Showing posts with label CTSA. Show all posts
Showing posts with label CTSA. Show all posts

Tuesday, February 26, 2013

The IOM wants to know how you feel about CTSAs (say what?)

By Kristin Schneeman, Program Director, FasterCures

Have you ever heard of a CTSA?  How about NCATS?  Does this feel a little like a word game – how many acronyms can you make out of these letters?

CTSAs are Clinical and Translational Science Awards, a significant program at the National Institutes of Health to fund – you guessed it – translational and clinical science and resources (as distinct from the more basic discovery science NIH has historically supported) at the nation’s most prominent academic research institutions, 60 in all, across the entire country. NCATS is the National Center for Advancing Translational Science, the newest Center at NIH which was created to “catalyze the generation of innovative methods and technologies” to support the translation of promising basic discoveries into new diagnostics and therapeutics for patients.

Last fall, NCATS asked the Institute of Medicine to conduct a review of the CTSA program, which at $461 million is the largest component of NCATS’ $575 million budget and its assets. I attended the most recent committee meeting at the end of January, which focused to a significant degree on the CTSAs’ “community engagement.” There was not much clarity about what “communities” were supposed to be engaged – in most cases they seem to be the geographic communities in which the CTSAs are located, but in some cases they seem to be the patient communities that researchers are interested in studying, which may or may not be local. Community engagement activities and research were in previous years required components of CTSA applications but are no longer; that was the source of some consternation at the meeting, with speakers lamenting that relationships painstakingly built over the course of the first five plus years of the program were at risk (and that new ones would not be a priority) if they aren’t a requirement of funding. Among the most eloquent speakers was Bray Patrick-Lake of the Clinical Trials Transformation Initiative, herself a patient advocate, who said trust and relationship-building are long-term endeavors, and that academic institutions need to invest in patient groups and “not just come running when you need them for a grant.”

Also notable at this meeting was the lack of focus on what might be done with the CTSAs as a network, as opposed to how the individual institutions are progressing and evolving. This does seem to have been taken up at previous IOM meetings as part of this review, but it was markedly absent during the discussions about future directions for the program that wrapped up this particular day. NCATS itself has made a principle for the next stage of the program that “the whole must be greater than the sum of its parts,” and many observers believe that great things could be achieved by connecting all these major institutions and allowing stakeholders both internal and external to better understand and access the expertise and resources that reside in them. There is a relatively new Coordinating Center which has begun working on developing shared resources such as IRBshare, Contractshare, and the Research Electronic Data Capture (REDCap) platform, which could benefit external stakeholders as well as the CTSAs themselves.

The IOM is accepting comments from the public about the CTSAs until March 1st.  We encourage you to take a look at the questions and to consider commenting.  Even if you aren’t familiar with the CTSAs, that might be worthy of comment in and of itself. Here are a few of the questions we’re focused on:
  • Are potential stakeholders aware of the resources available through the CTSA Program and are there barriers to use of those resources?
  • Have the CTSA institutions, individually and collectively, played an appropriate and adequate role in involving and interacting with community organizations and patient advocacy groups? 
  • Does the balance of CTSA Program efforts across the continuum of research from first phase studies in humans to clinical trials to population-based research on health outcomes and comparative effectiveness need to shift?
  • What do you see as successes, challenges, and future directions of the CTSA Program?

Tuesday, March 6, 2012

NCATS: Improving Outcomes from the Same Inputs


Last week, over 1,000 participants from all sectors of medical research participated in a virtual town hall with the interim leadership of the new National Center for Advancing Translational Science (NCATS) at NIH to discuss the status of the effort. NCATS is the first new Center at NIH in a dozen years.

Convened by
FasterCures as part of its Webinar series, it was a follow-up to a previous FasterCures web event held in March 2011 in which NIH director Francis Collins had laid out the vision for this new Center.

Dr. Tom Insel, acting director of NCATS (and director of the National Institute for Mental Health at NIH) laid out the Center’s mission, which in brief is “to pursue opportunities for disruptive innovation” in the process of translating promising discoveries into new diagnostics and therapeutics, and to “study the pathway and reengineer the pipeline” in ways that will benefit all players in the system. NCATS, he said, “is disease agnostic. We’re looking at generic innovations across many different diseases.”


Insel was careful to emphasize that the purpose of NCATS is to “facilitate — not duplicate — other translational research activities supported by NIH; to complement — not compete with — the private sector; and to reinforce — not reduce — NIH’s commitment to basic research.” He said that “most of the pieces of NCATS existed before [within NIH]. We’re trying to improve the outcomes from the same inputs.”

Insel summarized some of the
innovative programs that are now housed within or are being contemplated for NCATS, such as :
  • The NCATS Pharmaceutical Collection (NPC), a comprehensive resource of 3,800 approved and investigational medicines to facilitate repurposing of medicines;
  • Research Electronic Data Capture (REDCap), a Secure Web application that enables investigators to: create standardized surveys, easily transfer data, and export data into a variety of statistical programs;
  • The Learning Collaborative, a cross-sector collaboration to repurpose an approved drug for use in leukemia (which will be the topic of a FasterCures Webinar on March 21st);
  • An NIH‒FDA‒DARPA collaboration that aims to develop a tissue chip that mimics human physiology to screen for safe, effective drugs; and
  • An NIH–industry “compound rescuing initiative,” which would match compounds from pharma’s “virtual medicine cabinet” with NIH-funded scientists’ innovative ideas for new uses.
Margaret Anderson, FasterCures executive director who moderated the web meeting said that NIH’s efforts to establish NCATS is an efficient and effective way to thread the needle of existing work and make headway on de-risking the medical research process.

Dr. Chris Austin, Director of NCATS’s Division of Pre-Clinical Innovation and Dr. Kathy Hudson, NCATS Acting Deputy Director both answered questions from participants about collaboration with other stakeholders. Austin said he sees NCATS “as a collaborative instrument,” and that they are seeking the best ideas and best opportunities from outside researchers and funders. Hudson said “partnerships are an essential ingredient for NCATS,” and that input would be sought via a number of advisory groups, in addition to working with industry and other partners on specific projects.


Dr. Josephine Briggs, Acting Director of NCATS’s Division of Clinical Innovation, answered questions about the future of the Clinical and Translational Science Awards (CTSA) program, a network of 60 academic institutions which is the largest single component of NCATS, representing about 78% of its budget. She said that “the CTSA consortium is absolutely essential in the implementation of best practices” developed through NCATS, and that going forward NIH would be “focused on making sure the CTSAs are truly a networked consortium.”


Insel also noted that “unique and in some cases unprecedented scientific opportunities that exist drove the creation of NCATS.” He emphasized that this new center is a catalyst for medical progress, leveraging larger investments at the 26 other institutes and centers at NIH to make sure they have a greater impact. In the long term, he said, success will be measured on whether NCATS can catalyze clinical research to be “cheaper, faster, and better.”


Patients are waiting.